大行评级｜大和：上调药明生物目标价至35.5港元 重申“买入”评级
Ge Long Hui·2025-08-21 05:10

Core Viewpoint - Daiwa's report indicates that WuXi Biologics' performance in the first half of the year met expectations, with strong growth in revenue, gross margin, and backlog orders [1] Group 1: Financial Performance - Revenue, gross margin, and backlog orders all showed robust growth [1] - Gross margin forecasts for 2025 to 2027 have been raised by 1.5 to 1.6 percentage points [1] - Earnings per share forecast has been increased by 3% to 10% [1] Group 2: Cost Management - Sales and management expense forecasts have been reduced by 7% to reflect the latest trends in the first half of 2025 [1] Group 3: Target Price and Rating - The target price has been raised from HKD 30 to HKD 35.5 [1] - The "Buy" rating has been reaffirmed [1]